Pharmaceuticals & Biotechnology
Valuation | |
|---|---|
| Market Cap | 4.09 LCr |
| Price/Earnings (Trailing) | 37.42 |
| Price/Sales (Trailing) | 6.93 |
| EV/EBITDA | 22.46 |
| Price/Free Cashflow | 33.33 |
| MarketCap/EBT | 27.56 |
| Enterprise Value | 4.03 LCr |
Fundamentals | |
|---|---|
Growth & Returns | |
|---|---|
| Price Change 1W | 7.1% |
| Price Change 1M | -3.3% |
| Price Change 6M | 7.3% |
| Price Change 1Y | -2.9% |
| 3Y Cumulative Return | 18.5% |
| 5Y Cumulative Return | 21.8% |
| 7Y Cumulative Return | 21.5% |
| 10Y Cumulative Return | 7.4% |
| Revenue (TTM) |
| 58.94 kCr |
| Rev. Growth (Yr) | 13.8% |
| Earnings (TTM) | 10.95 kCr |
| Earnings Growth (Yr) | 16.1% |
Profitability | |
|---|---|
| Operating Margin | 27% |
| EBT Margin | 25% |
| Return on Equity | 13.42% |
| Return on Assets | 10.11% |
| Free Cashflow Yield | 3% |
Cash Flow & Liquidity |
|---|
| Cash Flow from Investing (TTM) | -5.31 kCr |
| Cash Flow from Operations (TTM) | 14.07 kCr |
| Cash Flow from Financing (TTM) | -7.91 kCr |
| Cash & Equivalents | 10.02 kCr |
| Free Cash Flow (TTM) | 11.94 kCr |
| Free Cash Flow/Share (TTM) | 49.78 |
Balance Sheet | |
|---|---|
| Total Assets | 1.04 LCr |
| Total Liabilities | 25.58 kCr |
| Shareholder Equity | 78.13 kCr |
| Current Assets | 60.14 kCr |
| Current Liabilities | 23.42 kCr |
| Net PPE | 10.41 kCr |
| Inventory | 10.44 kCr |
| Goodwill | 9.28 kCr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.05 |
| Debt/Equity | 0.06 |
| Interest Coverage | 50.11 |
| Interest/Cashflow Ops | 58.53 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 16.5 |
| Dividend Yield | 0.97% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | 0.00% |
Balance Sheet: Strong Balance Sheet.
Size: It is among the top 200 market size companies of india.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Profitability: Very strong Profitability. One year profit margin are 18%.
Technicals: Bullish SharesGuru indicator.
Past Returns: In past three years, the stock has provided 18.5% return compared to 12.8% by NIFTY 50.
Smart Money: Smart money has been increasing their position in the stock.
No major cons observed.
Balance Sheet: Strong Balance Sheet.
Size: It is among the top 200 market size companies of india.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Profitability: Very strong Profitability. One year profit margin are 18%.
Technicals: Bullish SharesGuru indicator.
Past Returns: In past three years, the stock has provided 18.5% return compared to 12.8% by NIFTY 50.
Smart Money: Smart money has been increasing their position in the stock.
No major cons observed.
Investor Care | |
|---|---|
| Dividend Yield | 0.97% |
| Dividend/Share (TTM) | 16.5 |
| Shares Dilution (1Y) | 0.00% |
| Earnings/Share (TTM) | 45.5 |
Financial Health | |
|---|---|
| Current Ratio | 2.57 |
| Debt/Equity | 0.06 |
Technical Indicators | |
|---|---|
| RSI (14d) | 50.62 |
| RSI (5d) | 84.38 |
| RSI (21d) | 47.24 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Buy |
| RSI Signal | Hold |
| RSI5 Signal | Sell |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal |
Updated Feb 5, 2026
Sun Pharma's consolidated net profit rose 16% year-on-year, reaching ₹3,369 crore.
The company's total revenue for the quarter increased to ₹15,520 crore from ₹13,675 crore year-over-year.
An interim dividend of ₹11 per equity share was approved by the board, reflecting strong financial performance.
Summary of Sun Pharmaceutical Industries's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
In the Q3 FY26 earnings call, Sun Pharmaceutical Industries Limited provided a positive outlook, highlighting strong sales growth, a robust balance sheet, and promising product launches. The company reported consolidated sales of Rs. 1,54,691 million for the quarter, a growth of 15.1% year-over-year. The executive team noted total sales growth, excluding milestone income, of 14.7%. The growth was fueled by a landmark income of US$55 million in the rest of the world.
Management pointed out the significant gross margin of 81%, attributed to an improved product mix, and an EBITDA of Rs. 49,485 million, reflecting a 23.4% increase compared to the previous year, with a margin of 31.9%. The reported net profit after tax was Rs. 33,688 million, a 16% increase, while the adjusted net profit stood at Rs. 35,367 million, up 9.9%. They declared an interim dividend of Rs. 11 per share.
Key forward-looking topics included:
This indicates management's strategic focus on sustainable growth, innovation, and market leadership, driven by promising products and robust financial health.
Understand Sun Pharmaceutical Industries ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| Shanghvi Finance Private Limited | 40.3% |
| Dilip. S. Shanghvi | 9.6% |
| Life Insurance Corporation Of India | 4.93% |
| Icici Prudential Value Fund | 4.06% |
| Sbi Nifty 50 Etf | 1.8% |
| Aditya Medisales Limited | 1.67% |
| Nps Trust- A/C Hdfc Pension Fund Management Limited Scheme E - Tier I |
Detailed comparison of Sun Pharmaceutical Industries against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| DIVISLAB | Divi's Lab | 1.63 LCr | 10.46 kCr | -7.50% | +0.30% | 65.62 | 15.59 | - | - |
| CIPLA | Cipla | 1.08 LCr | 29.37 kCr |
Comprehensive comparison against sector averages
SUNPHARMA metrics compared to Pharmaceuticals
| Category | SUNPHARMA | Pharmaceuticals |
|---|---|---|
| PE | 35.06 | 33.84 |
| PS | 6.49 | 4.69 |
| Growth | 10 % | 8.9 % |
Sun Pharmaceutical Industries is a prominent pharmaceuticals company, recognized by its stock ticker, SUNPHARMA. As of now, it boasts a market capitalization of Rs. 441,860.6 Crores.
Founded in 1983 and headquartered in Mumbai, India, Sun Pharmaceutical Industries develops, manufactures, and markets both branded and generic formulations along with active pharmaceutical ingredients (APIs). The company operates in various therapeutic areas, such as:
Additionally, it provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs.
Sun Pharmaceutical Industries offers a wide range of products including generic medications (tablets, capsules, injectables, inhalers, ointments, creams, and liquids), specialty medications, antiretrovirals, and over-the-counter products.
The company reported a trailing twelve-month revenue of Rs. 53,560.6 Crores and generated a profit of Rs. 11,469.6 Crores in the past four quarters, showcasing its profitability. Notably, the company has achieved a revenue growth of 38.6% over the last three years.
In terms of investor returns, Sun Pharmaceutical Industries distributes dividends with a yield of 1.3% per year, having returned Rs. 24 per share in the last twelve months.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
| Buy |
| SMA 20 Signal | Buy |
| SMA 50 Signal | Sell |
| SMA 100 Signal | Sell |
SUNPHARMA vs Pharmaceuticals (2021 - 2026)
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
This information is AI-generated and may contain inaccuracies. Please verify from multiple sources.
Question 1: "Could you walk us through your M&A strategy and what you are hoping to target or achieve with the strategy? Are you looking at tuck-ins, biosimilars, or expanding geographic presence?"
Answer: "The US remains a critical focus for us, particularly for innovative medicines. We're also considering smaller acquisitions in emerging markets to enhance our scale. Our strategy is disciplined; acquisitions are only pursued if they align with our long-term growth objectives. We aim to grow organically and be an attractive investment opportunity while ensuring any potential acquisition integrates well without losing focus."
Question 2: "On the innovative medicines sales, ex the milestone payment, the growth has been a bit soft compared to earlier quarters. Can you elaborate on that?"
Answer: "The growth appears lower partly due to a high base from prior one-time sales to partners last year. However, our specialty segment should sustain good performance. I recommend evaluating our business on an annualized basis instead of strictly by quarterly results, as that offers a clearer picture of our progress."
Question 3: "R&D spend on the innovative portfolio has been decreasing lately. Could you explain that?"
Answer: "The reduction relates to timing in beginning clinical trials. We are initiating new trials, including for GL0034, which should increase our R&D spend moving forward. We will provide a clearer direction for R&D expenditure next quarter, aligning our investments with our ongoing projects and future growth."
Question 4: "On US sales, what do you see happening with the generics business excluding Revlimid? Is it stable?"
Answer: "Excluding Lenalidomide, the generics business shows a slight decrease due to heightened competition on specific products. We're optimistic about recovery as we anticipate compliance in our manufacturing sites, enabling new product launches soon."
Question 5: "How are you planning to support the new product launches like LEQSELVI and UNLOXCYT?"
Answer: "Spending on product launches is evenly split between LEQSELVI and UNLOXCYT. Launch expenses are increasing as we've recently launched UNLOXCYT. This will become a core part of our operational expenses moving forward to support market growth."
Question 6: "What is the status of your pipeline for GL0034 in diabetes? When can we expect new data?"
Answer: "We're presenting Phase-2a data for GL0034 at upcoming scientific conferences. Our current Phase-2b study should conclude within 12 to 18 months, at which point we expect to share more substantial results."
Question 7: "Regarding the gross margins, what key drivers should we consider for sustaining high levels beyond Revlimid?"
Answer: "Although we don't provide specific product margins, a better mix of products has positively impacted our gross margins compared to last year. We aim to maintain these levels by optimizing our product offering and focusing on our core strengths."
Question 8: "What is your plan for the upcoming Semaglutide launch in India, and will you add to your sales force for supporting this product?"
Answer: "We anticipate launching Semaglutide and will add some field force to support this product introduction. However, predicting exact growth rates is challenging as market conditions evolve."
Question 9: "With your interest in biosimilars, how are you approaching this area now compared to the past?"
Answer: "We're reevaluating our potential in biosimilars, considering regulatory changes and costs. Our decisions will be based on comprehensive assessments that include manufacturing capabilities, investments, and market returns."
Question 10: "What is the role of UNLOXCYT in your product strategy regarding patient demographics?"
Answer: "UNLOXCYT is primarily positioned for new patients, focusing on its unique efficacy and tolerability profile. While some patients may transition from other therapies, our initial target remains those starting on new treatments."
| 1.58% |
| Raksha Sudhir Valia | 1.2% |
| Hdfc Trustee Company Ltd. A/C Hdfc Balanced Advantage Fund | 1.12% |
| Lakshdeep Investments & Finance (P) Ltd. | 1.02% |
| Sudhir Vrundavandas Valia | 0.6% |
| Unimed Investments Limited | 0.43% |
| Vibha Dilip Shanghvi | 0.37% |
| Vidhi Dilip Shanghvi | 0.12% |
| Aalok Dilip Shanghvi | 0.12% |
| Shanghvi Family & Friends Benefit Trust | 0.05% |
| Foreign Institutional Investors | 0% |
| Gujarat Sun Pharmaceutical Industries Pvt Ltd | 0% |
| Sanghvi Properties Private Limited | 0% |
| Flamboyawer Finance Private Limited | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
| -12.90% |
| -7.20% |
| 23.67 |
| 3.66 |
| - |
| - |
| DRREDDY | Dr. Reddy's Lab | 1.04 LCr | 36.09 kCr | -0.90% | +1.40% | 18.62 | 2.88 | - | - |
| LUPIN | Lupin | 1.01 LCr | 25.03 kCr | +3.20% | +1.50% | 23.42 | 4.05 | - | - |
| AUROPHARMA | Aurobindo Pharma | 68.63 kCr | 33.03 kCr | -4.00% | -0.90% | 20.05 | 2.08 | - | - |
Earnings Call Transcript • 04 Feb 2026 Q3FY26 Earnings Call Transcript |
Analyst / Investor Meet • 03 Feb 2026 Intimation of Schedule of Analyst/Institutional Investor Meeting |
General • 02 Feb 2026 Sustainability Report for FY 2024-25 |
Newspaper Publication • 01 Feb 2026 Newspaper Advertisements for Unaudited Financial Results for the quarter and nine months ended 31 December 2025 |
Change in Directorate • 31 Jan 2026 Board of Directors of the Company has approved the re-appointment of Dr. Pawan Goenka as Independent director for a second term of five years effective from 21 May 2026, and noted the cessation .... |
General • 31 Jan 2026 Q3FY26 Earnings Call audio recording |
Press Release / Media Release • 23 Jan 2026 Press release regarding intimation of DCGI approval to manufacture and market generic semaglutide injection in India for chronic weight management |
| 5.6% |
| 11,383 |
| 10,781 |
| 10,325 |
| 9,956 |
| 10,349 |
| 10,048 |
| Profit Before exceptional items and Tax | 13.2% | 4,717 | 4,168 | 3,991 | 3,616 | 3,793 | 3,598 |
| Exceptional items before tax | - | -489.48 | 0 | -818 | -361.68 | -316.17 | 0 |
| Total profit before tax | 1.4% | 4,227 | 4,168 | 3,173 | 3,254 | 3,476 | 3,598 |
| Current tax | -19.9% | 826 | 1,031 | 870 | 1,094 | 559 | 567 |
| Total tax | -19.9% | 826 | 1,031 | 870 | 1,094 | 559 | 567 |
| Total profit (loss) for period | 8.2% | 3,381 | 3,125 | 2,293 | 2,154 | 2,913 | 3,037 |
| Other comp. income net of taxes | -44.8% | 781 | 1,415 | 127 | 335 | 118 | 418 |
| Total Comprehensive Income | -8.3% | 4,162 | 4,540 | 2,420 | 2,489 | 3,031 | 3,455 |
| Earnings Per Share, Basic | 8.3% | 14 | 13 | 9.5 | 9 | 12.1 | 12.7 |
| Earnings Per Share, Diluted | 8.3% | 14 | 13 | 9.5 | 9 | 12.1 | 12.7 |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| Cost of Materials | 5.9% | 4,691 | 4,429 | 5,166 | 4,585 | 3,809 | 3,202 |
| Cost of Materials | - | - | - | - | - | - | - |
| Purchases of stock-in-trade | 36.9% | 1,360 | 994 | 1,126 | 1,249 | 1,200 | 1,227 |
| Purchases of stock-in-trade | - | - | - | - | - | - | - |
| Employee Expense | 9.9% | 2,608 | 2,374 | 2,157 | 2,001 | 1,798 | 1,703 |
| Employee Expense | - | - | - | - | - | - | - |
| Finance costs | 13.9% | 893 | 784 | 472 | 388 | 257 | 408 |
| Finance costs | - | - | - | - | - | - | - |
| Depreciation and Amortization | -22.7% | 1,238 | 1,601 | 1,601 | 1,350 | 587 | 562 |
| Depreciation and Amortization | - | - | - | - | - | - | - |
| Other expenses | 13.6% | 7,621 | 6,710 | 6,128 | 5,027 | 3,275 | 3,550 |
| Other expenses | - | - | - | - | - | - | - |
| Total Expenses | 7.4% | 18,342 | 17,072 | 16,412 | 14,417 | 10,711 | 10,790 |
| Total Expenses | - | - | - | - | - | - | - |
| Profit Before exceptional items and Tax | 37.1% | 5,031 | 3,669 | 4,679 | 2,127 | 2,242 | 3,253 |
| Profit Before exceptional items and Tax | - | - | - | - | - | - | - |
| Exceptional items before tax | 99.5% | 0 | -219.02 | -2,937.79 | -1,820.53 | -89.56 | 0 |
| Total profit before tax | 45.8% | 5,031 | 3,450 | 1,741 | 307 | 2,153 | 3,253 |
| Total profit before tax | - | - | - | - | - | - | - |
| Current tax | 53.9% | 909 | 591 | 50 | -33.75 | 13 | 42 |
| Current tax | - | - | - | - | - | - | - |
| Deferred tax | - | -160.67 | 0 | 0 | 441 | 0 | 0 |
| Total tax | 26.6% | 748 | 591 | 50 | 407 | 13 | 42 |
| Total tax | - | - | - | - | - | - | - |
| Total profit (loss) for period | 49.9% | 4,283 | 2,858 | 1,691 | -99.99 | 2,140 | 3,211 |
| Total profit (loss) for period | - | - | - | - | - | - | - |
| Other comp. income net of taxes | -61.5% | -23.2 | -13.98 | -11.01 | -91.62 | 63 | -80.8 |
| Other comp. income net of taxes | - | - | - | - | - | - | - |
| Total Comprehensive Income | 49.8% | 4,259 | 2,844 | 1,680 | -191.61 | 2,203 | 3,130 |
| Total Comprehensive Income | - | - | - | - | - | - | - |
| Earnings Per Share, Basic | 54.1% | 17.8 | 11.9 | 7 | -0.4 | 8.92 | 13.38 |
| Earnings Per Share, Basic | - | - | - | - | - | - | - |
| Earnings Per Share, Diluted | 54.1% | 17.8 | 11.9 | 7 | -0.4 | 8.92 | 13.38 |
| Earnings Per Share, Diluted | - | - | - | - | - | - | - |
| 36.7% |
| 769 |
| 563 |
| 517 |
| 388 |
| 304 |
| 329 |
| Goodwill | 0% | 121 | 121 | 121 | 121 | 121 | 121 |
| Non-current investments | 1.4% | 12,579 | 12,410 | 9 | 12,430 | 12,417 | 12,416 |
| Loans, non-current | 2% | 2,715 | 2,663 | 3,402 | 3,387 | 640 | 633 |
| Total non-current financial assets | 1.5% | 15,356 | 15,134 | 3,467 | 15,869 | 13,101 | 13,103 |
| Total non-current assets | 3% | 25,265 | 24,521 | 25,626 | 26,110 | 24,063 | 24,522 |
| Total assets | 5% | 45,419 | 43,273 | 42,005 | 41,065 | 41,233 | 40,987 |
| Borrowings, non-current | - | 809 | 0 | 11,601 | 11,036 | 10,558 | 7,587 |
| Total non-current financial liabilities | 615.7% | 1,189 | 167 | 13,283 | 12,280 | 11,461 | 8,159 |
| Provisions, non-current | 2.9% | 248 | 241 | 225 | 220 | 213 | 206 |
| Total non-current liabilities | 129.8% | 1,803 | 785 | 13,934 | 12,925 | 12,105 | 8,873 |
| Borrowings, current | 12.7% | 12,341 | 10,954 | 0 | 11 | 0 | 5.94 |
| Total current financial liabilities | 7.9% | 18,194 | 16,869 | 3,694 | 3,362 | 4,048 | 7,212 |
| Provisions, current | 4.4% | 524 | 502 | 479 | 609 | 738 | 810 |
| Current tax liabilities | 104.1% | 452 | 222 | - | - | - | - |
| Total current liabilities | 9.1% | 19,803 | 18,149 | 4,477 | 4,445 | 5,079 | 8,365 |
| Total liabilities | 14.1% | 21,606 | 18,934 | 18,412 | 17,370 | 17,185 | 17,239 |
| Equity share capital | 0% | 240 | 240 | 240 | 240 | 240 | 240 |
| Total equity | -2.2% | 23,813 | 24,340 | 23,593 | 23,694 | 24,048 | 23,748 |
| Total equity and liabilities | 5% | 45,419 | 43,273 | 42,005 | 41,065 | 41,233 | 40,987 |
| 8927.1% |
| 4,334 |
| 49 |
| 939 |
| 5,477 |
| - |
| - |
| Income taxes paid (refund) | -60.7% | 135 | 342 | 432 | -2,159.54 | - | - |
| Net Cashflows From Operating Activities | 1530.7% | 4,199 | -292.42 | 507 | 7,636 | - | - |
| Proceeds from sales of PPE | 300% | 57 | 15 | 8.3 | 46 | - | - |
| Purchase of property, plant and equipment | -5.1% | 711 | 749 | 962 | 850 | - | - |
| Proceeds from sales of investment property | -79.1% | 635 | 3,039 | 3,695 | 0 | - | - |
| Purchase of investment property | -77.3% | 644 | 2,833 | 3,693 | 0 | - | - |
| Cash receipts from repayment of advances and loans made to other parties | - | 633 | 0 | 6 | 813 | - | - |
| Dividends received | - | 0 | 0 | 0 | 14 | - | - |
| Interest received | -4.9% | 254 | 267 | 152 | 23 | - | - |
| Other inflows (outflows) of cash | - | -402.99 | 0 | 104 | -103.76 | - | - |
| Net Cashflows From Investing Activities | 20.2% | -209.56 | -262.91 | -705.17 | -2,702.1 | - | - |
| Proceeds from borrowings | -18.6% | 11,859 | 14,566 | 8,214 | 8,561 | - | - |
| Repayments of borrowings | 7.5% | 11,951 | 11,113 | 5,490 | 10,884 | - | - |
| Payments of lease liabilities | -6.5% | 30 | 32 | 35 | 37 | - | - |
| Dividends paid | 24.7% | 3,614 | 2,898 | 2,519 | 2,159 | - | - |
| Interest paid | 95.8% | 95 | 49 | 0.96 | 352 | - | - |
| Net Cashflows from Financing Activities | -910.2% | -3,831.18 | 474 | 169 | -4,870.85 | - | - |
| Effect of exchange rate on cash eq. | 289.8% | 7.53 | -2.44 | 20 | 5.06 | - | - |
| Net change in cash and cash eq. | 294.5% | 166 | -83.82 | -9.25 | 68 | - | - |